Revenue Growth and Strong Start to Fiscal 2025
The company reported a 9% revenue growth in the first quarter of 2025, reaching EUR 256.6 million, with a strong performance in the Biopharmaceutical and Diagnostics Solutions (BDS) Segment, which grew by 11%.
High-Value Solutions Growth
Revenue from high-value solutions grew 25% to EUR 110.3 million, accounting for 43% of total revenue, driven by strong demand for high-value syringes and stabilization in vial demand.
Improvement in Gross and Operating Profit Margins
Consolidated gross profit margin increased by 80 basis points to 27.2%, and the operating profit margin increased by 280 basis points to 13.5% due to strong performance in the BDS segment and cost-curtailing initiatives.
Positive Order Intake for Vials
Double-digit growth in order intake for both bulk and sterile vials, indicating a recovery in the vial market.
Progress in Capital Investment Projects
Significant progress in the Fishers and Latina facilities, with scaling of commercial syringe production and manufacturing line installations, supporting strong market demand.